Wound healing pathways via paracrine growth factor and cytokine signaling

Wound healing pathways via paracrine growth factor and cytokine signaling represent a complex, multi-stage biological process rather than a single molecular target. This network involves the coordinated release of signaling molecules, including Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor-beta (TGF-beta), and Fibroblast Growth Factor (FGF), which act on neighboring cells to orchestrate repair (StatPearls, 2023). These paracrine signals are critical for transitioning through the inflammatory, proliferative, and remodeling phases of healing (PubMed, PMC4217274). Dysregulation of these pathways is a primary driver of chronic non-healing wounds, such as diabetic ulcers, where growth factor levels are often insufficient (NIH, 2021). Therapeutic strategies often utilize recombinant versions of these factors, such as Becaplermin, to stimulate cellular migration and proliferation in impaired tissues (FDA, 2022). However, clinical application is complicated by the potential for promoting malignancy or causing pathological fibrosis and scarring (Journal of Investigative Dermatology, 2019). Consequently, while these pathways are vital therapeutic focuses, they represent a broad physiological system rather than a discrete drug target.

Other names

Paracrine signaling in wound repairGrowth factor and cytokine signaling in tissue regenerationIntercellular signaling in wound healing

Modulation of these pathways involves the administration of exogenous growth factors or cytokines that bind to specific cell-surface receptors (e.g., receptor tyrosine kinases), activating downstream intracellular signaling cascades such as MAPK/ERK, PI3K/Akt, and SMAD pathways to promote cellular processes essential for tissue repair (PubMed, PMC4217274).